Pulmonary Drug Delivery Systems Market – increasing demand with Industry Professionals: 3M Health Care, Allied Healthcare Products, Inc., AstraZeneca plc

Pulmonary drug delivery route is used to inhale medication through the respiratory tract. The medication reaches the blood stream through the alveolar surface of the lungs. Pulmonary route of drug administration is mainly used in the treatment of asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis.

Increasing prevalence of chronic obstructive pulmonary disease (COPD) is expected to propel growth of the global pulmonary drug delivery systems market over the forecast period. For instance, according to the study ‘Chronic Obstructive Pulmonary Disease in Latin America’, published in January 2019 in the journal Annals of Global Health, the prevalence of COPD in Latin American cities ranged between 6.2 and 19.6% in individuals aged 40 years and above.

Free Request a sample at: https://www.coherentmarketinsights.com/insight/request-sample/3952

Moreover, advantages associated with pulmonary drug delivery route are also expected to aid in growth of the market. These advantages include, ease of administration, requires low amount of drug compared to that in oral dosage, very less or negligible side effect, quick onset of action, drug degradation by liver is avoided, targeted drug delivery, and larger absorption area for lungs.

MDIs held dominant position in the global pulmonary drug delivery systems market in 2019, accounting for 53.9% share in terms of value, followed by DPIs and nebulizers, respectively

R&D in dry powder inhalation is expected to offer lucrative growth opportunities for players in the global pulmonary drug delivery systems market. For instance, in June 2020, researchers from University of Szeged, Hungary, reported development of a carrier-based DPI system, which is an interactive physical blend of a surface-modified carrier and a spray-dried drug with suitable shape and size for pulmonary application.

Moreover, adoption of vibrating mesh nebulizers for emerging therapeutics is expected to ensure adequate aerosol drug delivery, thereby aiding in growth of the market.

The global pulmonary drug delivery systems market was valued at US$ 28,700.0 Mn in 2019 and is forecast to reach a value of US$ 41,072.7 Mn by 2027 at a CAGR of 4.6% between 2020 and 2027.

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.